Format

Send to

Choose Destination
Clin Pharmacol Ther. 2018 Apr;103(4):591-598. doi: 10.1002/cpt.950. Epub 2017 Dec 20.

The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.

Author information

1
Seattle Children's Hospital, Seattle, Washington, USA.

Abstract

Several CAR T designs with CD19 specificity have been associated with consistent responses in clinical trials with complete remission (CR) rates ranging from 70-90%. Relevant challenges remain to be addressed, such as production time, early loss of CAR T cells, relapse due to loss of the target antigen, and prevention of severe cytokine release syndrome and neurotoxicity. This review describes constructs, clinical trial results, side effects, and future direction of CAR T-cell therapy in B-ALL.

PMID:
29171004
DOI:
10.1002/cpt.950
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center